Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

NCT00468767 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.

NCT NCT00468767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00468767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
Lead sponsor
Advanz Pharma
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2003
Completion date
November 30, 2004
Enrollment
356 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation